Clinical trials: Primary Central Nervous System Lymphoma
Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
This is a phase Ⅱ clinical study of Zanubrutinib(Z) in combination with methotrexate (M) and thiotepa(T) in treating newly diagnosed primary CNS lymphoma (PCNSL).
- Trial name
- NCT06646211
- Testing
- Zanubrutinib , Thiotepa, Methotrexate , Thiotepa and Zanubrutinib, ASCT±Zanubrutinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people…
- Conditions
- Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05681195
- Testing
- Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baptist Health South Florida
Primary Central Nervous System Lymphoma
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL
This study is a prospective, multicenter, open-label, single-arm clinical trial evaluating the safety and efficacy of the ZRMT (Zanubrutinib-Rituximab-Methotrexate-Temozolomide) regimen in the treatment of primary central nervous…
- Trial name
- NCT06445257
- Testing
- zanubrutinib 160 mg BID orally
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huai'an First People's Hospital
Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.
- Trial name
- NCT03581942
- Testing
- Ibrutinib, Copanlisib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Central Nervous System Tumors
Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）
In this trial, we will treat relapsed PCNSL with temozolomide, pemetrexed. Our objective was to assess our treatment strategies' availability based on response rates, progression-free survival (PFS), median PFS, and toxicity.
- Trial name
- NCT01985451
- Testing
- Pemetrexe, Temozolomide
- Volunteers
- 15 people
- Sponsor
- Rongjie Tao
Primary Central Nervous System Lymphoma
Methotrexate Early Toxicity Monitoring
High-dose methotrexate (MTX) is the main componement of first line treatment in primary central nervous system lymphoma. Renal toxicity is the main dose limiting toxicity because of major MTX elimination by the kidneys.
- Trial name
- METoxiM (NCT07406230)
- Testing
- methotrexate plasmatic dosing
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Glioma, Brain Tumor, Primary
Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory
To investigate a computer-based Cognitive Remediation Therapy (CRT) for brain tumor patients at the Massey Cancer Center on measures of cognitive functioning (e.g., working memory, attention, processing speed, language…
- Trial name
- NCT03323450
- Testing
- CogMed®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Central Nervous System Lymphoma
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
- Trial name
- NCT03684980
- Testing
- Methotrexate, Rituximab, leucovorin
- Where
- 11 sites in United States
- Volunteers
- 58 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable…
- Trial name
- NCT00504205
- Testing
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS)…
- Trial name
- NCT04609046
- Testing
- Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test
- Where
- 56 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.
- Trial name
- NCT01295463
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut Català d'Oncologia
Primary Central Nervous System Lymphoma (PCNSL)
Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma
To evaluate the efficacy and safety of relmacabtagene autoleucel combined with autologous hematopoietic stem cell transplantation, orelabrutinib, and sintilimab as first-line or relapsed/refractory treatment for primary central…
- Trial name
- NCT07198464
- Testing
- Relmacabtagene autoleucel and transplantation
- Volunteers
- 30 people
- Sponsor
- Zhengzhou University
Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
The purpose of this study is to measure the rate of complete response (CR and UCR) at the end of a course of immuno-chemotherapy: before cerebral radiotherapy for PCL after the course of immuno-chemotherapy for aggressive…
- Trial name
- NCT00553943
- Testing
- Rituximab, Cytarabine
- Where
- 46 sites in Belgium, France
- Volunteers
- 60 people
- Sponsor
- Lymphoma Study Association
Primary Central Nervous System Hodgkin Lymphoma
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
This phase II trial is evaluating the efficacy and side effect of orelabrutinib, sintilimab and temozolomide as possible treatments for relapsed or refractory central nervous system lymphoma.
- Trial name
- NCT04961515
- Testing
- Orelabrutinib, Sintilimab, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL Patients with relapsed refractory subtypes of DLBCL who…
- Conditions
- EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma, Primary Testicular Lymphoma
- Trial name
- DuRIANS (NCT03212807)
- Testing
- Durvalumab, Lenalidomide
- Where
- 4 sites in Singapore
- Sponsor
- Singapore General Hospital
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of EMD 121974 in treating patients with solid tumors or lymphoma. Cilengitide (EMD 121974) may stop the growth of cancer cells by stopping blood flow to the cancer
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00077155
- Testing
- cilengitide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Primary CNS Lymphoma (PCNSL)
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
An Open, Single treatment arm, Multi-center, Prospective, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) combined with Rituximab and Lenalidomide as a Salvage Therapy for Patients with Relapsed or Refractory…
- Trial name
- POTENTIAL-P (NCT06737250)
- Testing
- R2P -> RP
- Where
- 10 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- NOBO Medicine
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
This phase I clinical trial is studying the side effects and best dose of RO4929097 when given together with capecitabine in treating patients with refractory solid tumors.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma
- Trial name
- NCT01158274
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis
- Where
- 2 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098774
- Testing
- filgrastim, rituximab, cytarabine
- Where
- 30 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Primary Central Nervous System Lymphoma
Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients
Purpose of the study : To evaluate the antitumoral effect of two therapeutic procedures and to evaluate their respective toxicity on the CNS.
- Trial name
- PRECIS (NCT00863460)
- Testing
- cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, MTX based chemotherapy
- Where
- 23 sites in France
- Volunteers
- 140 people
- Sponsor
- Institut Curie